Preoperative use of enoxaparin and tirofiban: Possible association with increased bleeding postbypass

Anesthesiology

Volumn 91, Issue 3, 1999, Pages 869-872

  Skubas, Nikolaos J ^a   Despotis, George J ^a   Vlasnic, Jon J ^a   Moon, Marc R ^a  

^a Department of Anesthesiology Box 8054 ^*

Author keywords

Complications; Low molecular weight heparin; Platelet GP lIb IlIa inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FRESH FROZEN PLASMA; LOW MOLECULAR WEIGHT HEPARIN; METOPROLOL; PROTAMINE SULFATE; TIROFIBAN;

AGED; ANTICOAGULATION; ARTICLE; CASE REPORT; CORONARY ARTERY BYPASS SURGERY; ERYTHROCYTE TRANSFUSION; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE TRANSFUSION;

EID: 0032821193     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-199909000-00042     Document Type: Article

References (17)

1. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KAA, Premmereur J, Bigonzi F: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary disease. N Engl J Med 1997; 337:447-52
2. Weitz JI: Low-molecular-weight-heparins. N Engl J Med 1997; 337:688-98
3. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-5
4. Van Ryn-McKenna JV, Cai L, Ofusu FA, Hirsh J, Buchanan MR: Neutralization of enoxaparin-induced bleeding by protamine sulfate. Thromb Haemost 1990; 63:271-4
5. Ganjoo AK, Harloff MG, Johnson WD: Cardiopulmonary bypass for heparin-induced thrombcytopenia: Management with a heparin-bonded circuit and enoxaparin. J Thorac Cardiovasc Surg 1996; 112: 1390-2
6. Robitaille D, Leclerc JR, Laberg R, Sahab P, Atkinson S, Cartier R: Cardiopulmonary bypass with a low-molecular-weight heparin fraction (enoxaparin) in a patient with a history of heparin-induced thrombocytopenia. J Thorac Cardiovasc Surg 1992; 103:597-8
7. Braunwald E, Maserit A, Armstrong PW, Califf RM, Gibler WB, Hamm CW, Simmons ML, Van de Werf F: Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. Eur Heart J 1998; 19:(suppl D):D22-30
8. Bracey A, Radovancevic R, Vaughn W, Ferguson J, Livesay J: Blood use in emergency coronary artery bypass after receipt of abciximab during angioplasty (abstract). Transfusion 1998; 38:S250
9. Booth JE, Patel VB, Balog C, Miller DP, Juran NB, LeNarz L, Lincoff AM: Is bleeding risk increased in patients undergoing urgent coronary bypass surgery following abciximab? (abstract). Circulation 1998; 98: 1-845
10. Ferguson JJ, Kereiakes DJ, Adgey AAJ, Fox KAA, Hillegass WB, Pfisterer M, Vassanelli C: Safe use of platelet GP IIb/IIIa inhibitors. Eur Heart J 1998; 19:(suppl D):D40-51
11. Despotis GJ, Filos KS, Zoys TN, Hogue CW, Spitznagel E, Lappas DG: Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: A multivariate analysis in cardiac-surgical patients. Anest Analg 1996; 82:13-21
12. Barrett JS, Murphy G, Peerlinck K, De Lapeleire I, Gould RJ, Panebianco D, Hand E, Deckmyn H, Vermylen J: Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb-IIIa receptor antagonist, in healthy men. Clin Pharm Ther 1994; 56:377-88
13. Hirsh J, Levine MN: Low molecular weight heparin: Laboratory properties and clinical evaluation. Eur J Surg 1994; 571(suppl):9-22
14. Yin E: Appraisal of clot-based and amidolytic anti-Xa methods for the monitoring of heparin and its derivatives. Sem Thromb Hemostas 1985; 11:243-4
15. Despotis GJ, Ikonomakou S, Levine V, Joiner-Maier D, Santoro SA, Joist JH: Effects of platelets and white blood cells and antiplatelet agent c7E3 (Reopro™) on a new test of PAF procoagulant activity of whole blood. Thromb Res 1997; 86:205-19
16. Greilich PE, Alving BM, O'Neill KL, Chang AS, Reid TJ: A modified thromboelastographic method for monitoring c7E3 Fab in heparinized patients. Anesth Analg 1997; 84:31-8
17. Wakefield TW, Andrews PC, Wrobleski SK, Kadell AM, Tejwani S, Hulin MS, Stanley JC: A [+18RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low-molecular-weight heparin anticoagulation. J Surg Res 1996; 63:280-6